Longview Ventures

We welcome our lead investor Omega Funds and new investor Intuitive Ventures, and are grateful to our existing investors including founding investor Cleveland Clinic Innovations, Ajax Health, Broadview Ventures Inc, Longview Ventures, Aperture Venture Partners, JobsOhio Growth Capital Fund, CincyTech and our unnamed strategic investor. Saoussen Ben Halima, PhD Claudio Nessi Marla Jalbut, MD, MBA Murielle Thinard McLane Jotthe Kannappan Vijay Rajasekhar, MD, MBA Vivian Emmely Golfin, MD JD Friedland Zach Eisen Duke Rohlen Aftab Kherani Doug Koo Shane Kreidel Daniel Gottlieb Maria Berkman, MD Anthony Natale, M.D. Eric S. Tatyana Hower Steph Ison Samuel Lee, MD, MBA Ashley Keating Anthony Caparso John Sam Bhavesh Patel Rabih Nassif Andrew Wu

We are excited to announce that we have successfully closed $28M in our Series C financing round. Funding from this round will support regulatory submissions for our temporary pacing platform and the pilot study for our third generation EV-ICD lead system. Congrats to the entire AtaCor team on this important milestone! Read the full announcement here (https://lnkd.in/gBP7ji6j). #atacor #cardiology #CRM @HRS #EV-ICD

Today marks an exciting milestone at Basking: We announced the close of our $55m financing, led by ARCH Venture Partners, plus participation from additional new investors Insight Partners, Platanus, Solas BioVentures and RTW Investments, LP, as well as existing investors Longview Ventures, Rev1 Ventures and The Ohio State University. Thank you to our team, investors and advisors. #AIS #stroke #drugdevelopment #financing #clinicalresearch https://lnkd.in/eUZNkeup

We’re thrilled to announce the closing of an oversubscribed $75 million Series B financing. This capital investment by a top-tier syndicate will enable us to advance our mission to develop and make globally available the first treatment targeting a root cause of preeclampsia: over-production of the protein sFlt1 by the placenta. Existing investors GV (Google Ventures), F-Prime Capital, Lilly Asia Ventures 礼来亚洲基金, and Longview Healthcare Ventures participated in the Series B round, joined by new investors New Enterprise Associates (NEA), who led the round, and Atlas Venture. Concurrent with the Series B raise, Scott Gottlieb, M.D., Partner at NEA and former Commissioner of the FDA, and David Grayzel, M.D., Partner at Atlas Venture, have joined our Board of Directors. Read our press release to learn more about the extraordinary, complex unmet needs in preeclampsia, and our breakthrough science and drug candidate, CBP-4888, to potentially deliver a solution: https://bit.ly/425OlVc #preeclampsia #maternalhealth #pregnancy #siRNA #RNA